Canaan X L.p. - Net Worth and Insider Trading
Canaan X L.p. Net Worth
The estimated net worth of Canaan X L.p. is at least $194 Million dollars as of 2024-09-20. Canaan X L.p. is the 10% Owner of Protagonist Therapeutics Inc and owns about 2,116,552 shares of Protagonist Therapeutics Inc (PTGX) stock worth over $97 Million. Canaan X L.p. is the 10% Owner of IDEAYA Biosciences Inc and owns about 2,660,713 shares of IDEAYA Biosciences Inc (IDYA) stock worth over $94 Million. Canaan X L.p. is also the 10% Owner of NextCure Inc and owns about 2,254,442 shares of NextCure Inc (NXTC) stock worth over $3 Million. Besides these, Canaan X L.p. also holds Iterum Therapeutics PLC (ITRM) . Details can be seen in Canaan X L.p.'s Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Canaan X L.p. has not made any transactions after 2019-05-28 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Canaan X L.p.
Canaan X L.p. Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Canaan X L.p. owns 5 companies in total, including Iterum Therapeutics PLC (ITRM) , IDEAYA Biosciences Inc (IDYA) , and NextCure Inc (NXTC) among others .
Click here to see the complete history of Canaan X L.p.’s form 4 insider trades.
Insider Ownership Summary of Canaan X L.p.
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ITRM | Iterum Therapeutics PLC | 2020-01-21 | director & 10 percent owner |
| IDYA | IDEAYA Biosciences Inc | 2019-05-28 | 10 percent owner |
| NXTC | NextCure Inc | 2019-05-13 | 10 percent owner |
 | | 2018-05-17 | 10 percent owner |
| | 2021-06-30 | 10 percent owner |
Canaan X L.p. Latest Holdings Summary
Canaan X L.p. currently owns a total of 4 stocks. Among these stocks, Canaan X L.p. owns 2,116,552 shares of Protagonist Therapeutics Inc (PTGX) as of May 17, 2018, with a value of $97 Million and a weighting of 49.99%. Canaan X L.p. owns 2,660,713 shares of IDEAYA Biosciences Inc (IDYA) as of May 28, 2019, with a value of $94 Million and a weighting of 48.29%. Canaan X L.p. also owns 2,254,442 shares of NextCure Inc (NXTC) as of May 13, 2019, with a value of $3 Million and a weighting of 1.66%. The other 1 stocks Iterum Therapeutics PLC (ITRM) have a combined weighting of 0.06% among all his current holdings.
Latest Holdings of Canaan X L.p.
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| PTGX | Protagonist Therapeutics Inc | 2018-05-17 | 2,116,552 | 45.92 | 97,192,068 |
| IDYA | IDEAYA Biosciences Inc | 2019-05-28 | 2,660,713 | 35.29 | 93,896,562 |
| NXTC | NextCure Inc | 2019-05-13 | 2,254,442 | 1.43 | 3,223,852 |
| ITRM | Iterum Therapeutics PLC | 2018-05-30 | 115,545 | 1.09 | 125,944 |
Holding Weightings of Canaan X L.p.
Canaan X L.p. Form 4 Trading Tracker
According to the SEC Form 4 filings, Canaan X L.p. has made a total of 0 transactions in Protagonist Therapeutics Inc (PTGX) over the past 5 years. The most-recent trade in Protagonist Therapeutics Inc is the sale of 38,968 shares on May 17, 2018, which brought Canaan X L.p. around $237,315.
According to the SEC Form 4 filings, Canaan X L.p. has made a total of 0 transactions in IDEAYA Biosciences Inc (IDYA) over the past 5 years. The most-recent trade in IDEAYA Biosciences Inc is the acquisition of 400,000 shares on May 28, 2019, which cost Canaan X L.p. around $4 Million.
According to the SEC Form 4 filings, Canaan X L.p. has made a total of 0 transactions in NextCure Inc (NXTC) over the past 5 years. The most-recent trade in NextCure Inc is the acquisition of 50,000 shares on May 13, 2019, which cost Canaan X L.p. around $750,000.
More details on Canaan X L.p.'s insider transactions can be found in the Insider Trading History of Canaan X L.p. table.Insider Trading History of Canaan X L.p.
- 1
Canaan X L.p. Trading Performance
GuruFocus tracks the stock performance after each of Canaan X L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Canaan X L.p. is 20.83%. GuruFocus also compares Canaan X L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Canaan X L.p. within 3 months outperforms 2 times out of 4 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Canaan X L.p.'s insider trading performs compared to the benchmark.
Performance of Canaan X L.p.
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -4.86 | | | | | |
| Relative Return to S&P 500(%) | -6.31 | | | | | |
Canaan X L.p. Ownership Network
Canaan X L.p. Owned Company Details
What does Iterum Therapeutics PLC do?
Who are the key executives at Iterum Therapeutics PLC?
Canaan X L.p. is the director & 10 percent owner of Iterum Therapeutics PLC. Other key executives at Iterum Therapeutics PLC include Chief Scientific Officer Michael W. Dunne , director & President & CEO Fishman Corey N. , and Chief Medical Officer Sailaja Puttagunta .
Iterum Therapeutics PLC (ITRM) Insider Trades Summary
Over the past 18 months, Canaan X L.p. made no insider transaction in Iterum Therapeutics PLC (ITRM). Other recent insider transactions involving Iterum Therapeutics PLC (ITRM) include a net purchase of 55,000 shares made by Michael W. Dunne , and a net purchase of 10,000 shares made by Fishman Corey N. .
In summary, during the past 3 months, insiders sold 0 shares of Iterum Therapeutics PLC (ITRM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Iterum Therapeutics PLC (ITRM) were sold and 65,000 shares were bought by its insiders, resulting in a net purchase of 65,000 shares.
Iterum Therapeutics PLC (ITRM)'s detailed insider trading history can be found in Insider Trading Tracker table.
Iterum Therapeutics PLC Insider Transactions
Canaan X L.p. Mailing Address
Above is the net worth, insider trading, and ownership report for Canaan X L.p.. You might contact Canaan X L.p. via mailing address: 2765 Sand Hill Rd, Menlo Park Ca 94025.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
